{"id":14041,"date":"2019-03-08T08:00:55","date_gmt":"2019-03-08T07:00:55","guid":{"rendered":"http:\/\/www.cde.ual.es\/?p=14041"},"modified":"2019-03-05T10:37:49","modified_gmt":"2019-03-05T09:37:49","slug":"imminent-anti-metastatic-vaccine-for-prostate-cancer","status":"publish","type":"post","link":"https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/","title":{"rendered":"Imminent anti-metastatic vaccine for prostate cancer"},"content":{"rendered":"

Prostate cancer is the most commonly diagnosed cancer in men with millions of new cases every year. European scientists have developed a novel vaccine to prevent disease metastasis, the main cause of mortality amongst advanced prostate cancer sufferers.<\/strong><\/em><\/p>\n


\n\"\"<\/a><\/p>\n

The majority of prostate cancer patients are diagnosed at the localised, pre-metastatic stage of the disease. They have to undergo primary tumour excision by surgery or radiotherapy followed by active monitoring to ensure cancer relapse doesn\u2019t occur. Despite the frequent incidence of metastasis formation, there is currently no treatment available post-surgery to directly limit micro-metastasis formation.<\/p>\n

Available treatments exhibit serious side effects, mainly focus on later stages of cancer progression and almost always develop resistance. There is an urgent need for therapeutic strategies that act early on in prostate cancer before cancer returns and cancer cells start to spread, making the treatment far more difficult and expensive.<\/p>\n

Clinical impact<\/h2>\n

So far, the vaccine has been tested in prostate cancer patients after removal of the primary tumour and before metastasis formation to address the challenge posed by the high incidence of metastasis following primary tumour excision. Results from the phase I\/II clinical trial, which involved 22 patients after prostatectomy, demonstrated the excellent tolerability and safety of RV001. Importantly, the majority (86 %) of patients showed a significantly positive immune response.<\/p>\n

As Dr Borghei outlines: \u201cthe next step is to validate the efficacy of the drug in a Phase IIb clinical trial in a larger number of patients.\u2033 Nonetheless, she emphasises the need for partnerships and capital investment to secure successful commercialisation of the vaccine.<\/p>\n

RV001 has the potential to be administered to more than 150 000 patients in Europe and US alone, helping them at an early stage to reduce prostate cancer burden. This will bring in an estimated revenue of EUR 1 billion by 2030.<\/p>\n

RV001 holds important competitive advantages such as targeting a stage of the disease where there is currently no treatment available coupled with high safety and cost-effectiveness. At the same time, scientists are confident it will work against multiple types of metastatic cancer.<\/p>\n

More Information<\/h2>\n

Access to the full new<\/a><\/h2>\n","protected":false},"excerpt":{"rendered":"

Prostate cancer is the most commonly diagnosed cancer in men with millions of new cases every year. European scientists have developed a novel vaccine to prevent disease metastasis, the main cause of mortality amongst advanced prostate cancer sufferers. The majority of prostate cancer patients are diagnosed at the localised, pre-metastatic stage of the disease. They […]<\/p>\n","protected":false},"author":101012,"featured_media":14037,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":""},"categories":[346],"tags":[406,368,354,404,350,405],"class_list":{"0":"post-14041","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-eu-news","8":"tag-european","9":"tag-european-union","10":"tag-innovacion-en","11":"tag-innovation","12":"tag-investigacion-en","13":"tag-investigation","14":"entry"},"acf":[],"yoast_head":"\nImminent anti-metastatic vaccine for prostate cancer | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Imminent anti-metastatic vaccine for prostate cancer | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda\" \/>\n<meta property=\"og:description\" content=\"Prostate cancer is the most commonly diagnosed cancer in men with millions of new cases every year. European scientists have developed a novel vaccine to prevent disease metastasis, the main cause of mortality amongst advanced prostate cancer sufferers. The majority of prostate cancer patients are diagnosed at the localised, pre-metastatic stage of the disease. They […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/cdeuniversidadalmeria\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-08T07:00:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2019\/03\/nurse-527622_1920.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1276\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"BECACDE1\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@cdeualmeria\" \/>\n<meta name=\"twitter:site\" content=\"@cdeualmeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BECACDE1\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/imminent-anti-metastatic-vaccine-for-prostate-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/imminent-anti-metastatic-vaccine-for-prostate-cancer\\\/\"},\"author\":{\"name\":\"BECACDE1\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#\\\/schema\\\/person\\\/bf2f837cf3353e2161fe1087adbd728f\"},\"headline\":\"Imminent anti-metastatic vaccine for prostate cancer\",\"datePublished\":\"2019-03-08T07:00:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/imminent-anti-metastatic-vaccine-for-prostate-cancer\\\/\"},\"wordCount\":353,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/imminent-anti-metastatic-vaccine-for-prostate-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2019\\\/03\\\/nurse-527622_1920.jpg\",\"keywords\":[\"European\",\"European Union\",\"Innovaci\u00f3n\",\"innovation\",\"Investigaci\u00f3n\",\"investigation\"],\"articleSection\":[\"EU News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/imminent-anti-metastatic-vaccine-for-prostate-cancer\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/imminent-anti-metastatic-vaccine-for-prostate-cancer\\\/\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/imminent-anti-metastatic-vaccine-for-prostate-cancer\\\/\",\"name\":\"Imminent anti-metastatic vaccine for prostate cancer | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/imminent-anti-metastatic-vaccine-for-prostate-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/imminent-anti-metastatic-vaccine-for-prostate-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2019\\\/03\\\/nurse-527622_1920.jpg\",\"datePublished\":\"2019-03-08T07:00:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/imminent-anti-metastatic-vaccine-for-prostate-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/imminent-anti-metastatic-vaccine-for-prostate-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/imminent-anti-metastatic-vaccine-for-prostate-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2019\\\/03\\\/nurse-527622_1920.jpg\",\"contentUrl\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2019\\\/03\\\/nurse-527622_1920.jpg\",\"width\":1920,\"height\":1276},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/imminent-anti-metastatic-vaccine-for-prostate-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EU News\",\"item\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/category\\\/eu-news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Imminent anti-metastatic vaccine for prostate cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#website\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/\",\"name\":\"CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda\",\"description\":\"Centro de Documentaci\u00f3n Europea de la Universidad de Almer\u00eda\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#organization\"},\"alternateName\":\"CDE Almer\u00eda\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cde.ual.es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#organization\",\"name\":\"Centro de Documentaci\u00f3n Europea de Almer\u00eda\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/cde-logo-3.png\",\"contentUrl\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/cde-logo-3.png\",\"width\":1400,\"height\":300,\"caption\":\"Centro de Documentaci\u00f3n Europea de Almer\u00eda\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/cdeuniversidadalmeria\\\/\",\"https:\\\/\\\/x.com\\\/cdeualmeria\",\"https:\\\/\\\/www.tiktok.com\\\/@cdealmeria\",\"https:\\\/\\\/www.instagram.com\\\/cdealmeria\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/cde-almera-812b26a9\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#\\\/schema\\\/person\\\/bf2f837cf3353e2161fe1087adbd728f\",\"name\":\"BECACDE1\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g\",\"caption\":\"BECACDE1\"},\"sameAs\":[\"http:\\\/\\\/www.cdealmeria.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Imminent anti-metastatic vaccine for prostate cancer | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Imminent anti-metastatic vaccine for prostate cancer | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","og_description":"Prostate cancer is the most commonly diagnosed cancer in men with millions of new cases every year. European scientists have developed a novel vaccine to prevent disease metastasis, the main cause of mortality amongst advanced prostate cancer sufferers. The majority of prostate cancer patients are diagnosed at the localised, pre-metastatic stage of the disease. They […]","og_url":"https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/","og_site_name":"CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","article_publisher":"https:\/\/www.facebook.com\/cdeuniversidadalmeria\/","article_published_time":"2019-03-08T07:00:55+00:00","og_image":[{"width":1920,"height":1276,"url":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2019\/03\/nurse-527622_1920.jpg","type":"image\/jpeg"}],"author":"BECACDE1","twitter_card":"summary_large_image","twitter_creator":"@cdeualmeria","twitter_site":"@cdeualmeria","twitter_misc":{"Written by":"BECACDE1","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/#article","isPartOf":{"@id":"https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/"},"author":{"name":"BECACDE1","@id":"https:\/\/www.cde.ual.es\/#\/schema\/person\/bf2f837cf3353e2161fe1087adbd728f"},"headline":"Imminent anti-metastatic vaccine for prostate cancer","datePublished":"2019-03-08T07:00:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/"},"wordCount":353,"commentCount":0,"publisher":{"@id":"https:\/\/www.cde.ual.es\/#organization"},"image":{"@id":"https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2019\/03\/nurse-527622_1920.jpg","keywords":["European","European Union","Innovaci\u00f3n","innovation","Investigaci\u00f3n","investigation"],"articleSection":["EU News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/","url":"https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/","name":"Imminent anti-metastatic vaccine for prostate cancer | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","isPartOf":{"@id":"https:\/\/www.cde.ual.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2019\/03\/nurse-527622_1920.jpg","datePublished":"2019-03-08T07:00:55+00:00","breadcrumb":{"@id":"https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/#primaryimage","url":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2019\/03\/nurse-527622_1920.jpg","contentUrl":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2019\/03\/nurse-527622_1920.jpg","width":1920,"height":1276},{"@type":"BreadcrumbList","@id":"https:\/\/www.cde.ual.es\/en\/imminent-anti-metastatic-vaccine-for-prostate-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/www.cde.ual.es\/en\/"},{"@type":"ListItem","position":2,"name":"EU News","item":"https:\/\/www.cde.ual.es\/en\/category\/eu-news\/"},{"@type":"ListItem","position":3,"name":"Imminent anti-metastatic vaccine for prostate cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.cde.ual.es\/#website","url":"https:\/\/www.cde.ual.es\/","name":"CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","description":"Centro de Documentaci\u00f3n Europea de la Universidad de Almer\u00eda","publisher":{"@id":"https:\/\/www.cde.ual.es\/#organization"},"alternateName":"CDE Almer\u00eda","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cde.ual.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.cde.ual.es\/#organization","name":"Centro de Documentaci\u00f3n Europea de Almer\u00eda","url":"https:\/\/www.cde.ual.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cde.ual.es\/#\/schema\/logo\/image\/","url":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2025\/07\/cde-logo-3.png","contentUrl":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2025\/07\/cde-logo-3.png","width":1400,"height":300,"caption":"Centro de Documentaci\u00f3n Europea de Almer\u00eda"},"image":{"@id":"https:\/\/www.cde.ual.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/cdeuniversidadalmeria\/","https:\/\/x.com\/cdeualmeria","https:\/\/www.tiktok.com\/@cdealmeria","https:\/\/www.instagram.com\/cdealmeria\/","https:\/\/www.linkedin.com\/in\/cde-almera-812b26a9\/"]},{"@type":"Person","@id":"https:\/\/www.cde.ual.es\/#\/schema\/person\/bf2f837cf3353e2161fe1087adbd728f","name":"BECACDE1","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g","caption":"BECACDE1"},"sameAs":["http:\/\/www.cdealmeria.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/posts\/14041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/users\/101012"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/comments?post=14041"}],"version-history":[{"count":0,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/posts\/14041\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/media\/14037"}],"wp:attachment":[{"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/media?parent=14041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/categories?post=14041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/tags?post=14041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}